On June 2, 2016, the Company held its 2016 Annual Meeting of Stockholders in Incline Village, Nevada. At the annual meeting, the Companys stockholders: (i) elected each of Harold E. Selick, Ph.D., Paul R. Edick and Samuel R. Saks, M.D. to the Companys Board of Directors for a term of three years, (ii) ratified the appointment of PricewaterhouseCoopers LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016, and (iii) approved, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys 2016 proxy statement.

Represented in person or by proxy at the annual meeting were 142,989,966 shares of the Companys common stock, or 86.6% of the total number of shares outstanding as of the recor d date. The results of the matters submitted to a stockholder vote at the annual meeting were as follows.

1.Election of Directors:

Name

For

Withheld

Broker Non-Votes

Harold E. Selick, Ph.D.

104,551,441

4,751,258

33,687,267

Paul R. Edick

107,097,015

2,205,684

33,687,267

Samuel R. Saks, M.D.

106,927,147

2,375,552

33,687,267

2.

Ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2016:

For

Against

Abstain

141,253,541

1,222,892

513,533

3.

Approve, on an advisory basis, the compensation of the Companys named executive officers as disclosed in the Companys proxy statement:

For

Against

Abstain

Broker Non-Votes

103,938,223

4,541,790

822,686

33,687,267

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.

(Company)

By:

/s/ Christopher Stone

Christopher Stone

Vice President, General Counsel and Secretary

Dated:

June3, 2016

makes a similar move, sign up!

Other recent filings from the company include the following:

Current report, items 7.01 and 9.01 - Nov. 14, 2017
PDL BioPharma Just Filed Its Quarterly Report: 2. Net Income per Sh... - Nov. 13, 2017
Notification of inability to timely file Form 10-Q or 10-QSB - Nov. 13, 2017
Pdl Biopharma’S Proposal To Acquire Neos Therapeutics Expires Today; - Nov. 8, 2017
PDL: Cook Williams Communications, Inc - Nov. 2, 2017

Auto Refresh

Feedback